Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

NCT00044694 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Non-Insulin-Dependent

Interventions

DRUG: Placebo 0.01 mL
DRUG: Placebo 0.02 mL
DRUG: Placebo 0.03 mL
DRUG: Placebo 0.04 mL
DRUG: AC2993 2.5 mcg
DRUG: AC2993 5.0 mcg
DRUG: AC2993 7.5 mcg
DRUG: AC2993 10.0 mcg

Sponsor

AstraZeneca